Starling Oncology, Inc. (STLN)
NASDAQ: STLN · Real-Time Price · USD
5.17
+0.04 (0.78%)
At close: Aug 4, 2026
Starling Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue | 545.76 | 502.73 | 393.41 | 324.24 | 252.48 | 203 |
Revenue Growth | 35.37% | 27.79% | 21.33% | 28.42% | 24.37% | 8.26% |
Cost of Revenue | 463.26 | 426.29 | 339.42 | 264.67 | 200.39 | 162.16 |
Gross Profit | 82.5 | 76.44 | 54 | 59.57 | 52.09 | 40.85 |
Selling, General & Admin | 108.41 | 105.57 | 107.83 | 113.85 | 119.69 | 82.89 |
Operating Expenses | 115.19 | 112.52 | 114.12 | 119.72 | 124.1 | 86.23 |
Operating Income | -32.69 | -36.08 | -60.12 | -60.15 | -72.01 | -45.38 |
Interest Expense | -11.14 | -11.28 | -7.5 | -6.78 | -4.08 | -0.32 |
Other Non Operating Income (Expenses) | -3.33 | -13.38 | 2.82 | -0.35 | 25.9 | 3.71 |
EBT Excluding Unusual Items | -47.16 | -60.74 | -64.8 | -67.28 | -50.19 | -41.99 |
Merger & Restructuring Charges | - | - | - | - | - | -0.48 |
Impairment of Goodwill | - | - | - | -16.87 | -9.94 | - |
Gain (Loss) on Sale of Investments | 0.01 | 0.01 | 0.13 | 0.24 | 0.64 | - |
Other Unusual Items | 3.5 | - | - | 0.8 | 59.4 | 30.87 |
Pretax Income | -43.64 | -60.74 | -64.66 | -83.1 | -0.09 | -11.6 |
Income Tax Expense | -0.13 | -0.13 | - | -0.04 | -0.24 | -0.67 |
Net Income | -43.51 | -60.61 | -64.66 | -83.07 | 0.15 | -10.93 |
Preferred Dividends & Other Adjustments | -7.19 | -10.3 | -11.66 | -15.19 | 0.08 | -0.3 |
Net Income to Common | -36.32 | -50.31 | -53.01 | -67.88 | 0.07 | -10.63 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 99 | 92 | 75 | 74 | 73 | 66 |
Shares Outstanding (Diluted) | 99 | 92 | 75 | 74 | 81 | 66 |
Shares Change | 30.10% | 23.11% | 1.76% | -8.51% | 21.70% | 12.03% |
EPS (Basic) | -0.37 | -0.54 | -0.71 | -0.92 | 0.00 | -0.16 |
EPS (Diluted) | -0.37 | -0.54 | -0.71 | -0.92 | -0.21 | -0.16 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -25.73 | -27.79 | -30.33 | -40.88 | -67.29 | -35.53 |
Free Cash Flow Per Share | -0.26 | -0.30 | -0.40 | -0.55 | -0.83 | -0.54 |
Gross Margin | 15.12% | 15.20% | 13.73% | 18.37% | 20.63% | 20.12% |
Operating Margin | -5.99% | -7.18% | -15.28% | -18.55% | -28.52% | -22.36% |
Profit Margin | -6.66% | -10.01% | -13.47% | -20.93% | 0.03% | -5.24% |
Free Cash Flow Margin | -4.71% | -5.53% | -7.71% | -12.61% | -26.65% | -17.50% |
EBITDA | -25.91 | -29.14 | -53.83 | -54.28 | -67.6 | -42.04 |
EBITDA Margin | -4.75% | -5.80% | -13.68% | -16.74% | -26.77% | -20.71% |
D&A For EBITDA | 6.78 | 6.94 | 6.29 | 5.87 | 4.41 | 3.34 |
EBIT | -32.69 | -36.08 | -60.12 | -60.15 | -72.01 | -45.38 |
EBIT Margin | -5.99% | -7.18% | -15.28% | -18.55% | -28.52% | -22.36% |
Revenue as Reported | 545.76 | 502.73 | 393.41 | 324.24 | 252.48 | 203 |